Abstract
Li–Fraumeni syndrome is an autosomal dominant disorder characterized by germline TP53 mutation and increased susceptibility to cancer. Despite certain in vitro findings and a theoretical rationale for patients with TP53 mutation to be more radiosensitive and more prone to developing radiotherapy (RT)–induced secondary malignancies, corresponding clinical data remain elusive. Here, we report the case of a woman with TP53 mutation who was treated with adjuvant pelvic RT for stage ib uterine leiomyosarcoma in 2000, with radioactive iodine for papillary thyroid cancer in 2001, and with palliative RT to the humerus in 2010 for metastatic uterine leiomyosarcoma. She has not developed any acute or late RT-related toxicity, nor any secondary malignancies, since her first RT treatment. The literature review describes the potential risks and benefits of using irradiation in patients with TP53 mutation.